GSK (LON:GSK) Issues Earnings Results

GSK (LON:GSK) announced its quarterly earnings data on Wednesday. The company reported GBX 23.20 ($0.29) earnings per share (EPS) for the quarter, Digital Look Earnings reports. GSK had a net margin of 12.83% and a return on equity of 33.30%.

GSK Stock Performance

GSK stock opened at GBX 1,500.50 ($18.76) on Thursday. The company has a debt-to-equity ratio of 123.04, a current ratio of 0.82 and a quick ratio of 0.73. GSK has a 1-year low of GBX 1,282.50 ($16.03) and a 1-year high of GBX 1,823.50 ($22.80). The business has a 50-day moving average price of GBX 1,353.92 and a 200 day moving average price of GBX 1,457.61. The company has a market capitalization of £61.22 billion, a P/E ratio of 1,327.88, a PEG ratio of 1.24 and a beta of 0.31.

Insider Buying and Selling at GSK

In related news, insider Jonathan Symonds bought 1,500 shares of the company’s stock in a transaction on Friday, December 20th. The shares were acquired at an average price of GBX 1,315 ($16.44) per share, with a total value of £19,725 ($24,659.33). Insiders own 1.61% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on the company. Berenberg Bank cut their price objective on GSK from GBX 1,820 ($22.75) to GBX 1,600 ($20.00) and set a “buy” rating on the stock in a research report on Friday, November 29th. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a research note on Tuesday, January 7th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of GBX 1,805.83 ($22.58).

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.